title: Duration and magnitude of action of 50 and 100 micrograms of inhaled salmeterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in subjects with asthma.
authors.affiliation: Department of Chest Medicine, Hôpital du Sacré-Coeur, Montreal, Quebec, Canada.
authors.forename: A
authors.initials: A
authors.lastname: Cartier
authors.forename: H
authors.initials: H
authors.lastname: Ghezzo
authors.forename: J
authors.initials: J
authors.lastname: L'Archevêque
authors.forename: C
authors.initials: C
authors.lastname: Trudeau
authors.forename: J L
authors.initials: JL
authors.lastname: Malo
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000388:Air; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology*; D016084:Bronchoconstriction / Q000187:drug effects*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D003080:Cold Temperature / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D000068299:Salmeterol Xinafoate; D013997:Time Factors
chemical_list: D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000420:Albuterol